Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario

Abstract Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multicenter real-world outcomes and the contribution of up-front consolidation post-TAG remain less defined. We retrospectively analyzed 32 patients with BPDCN treated with frontline TAG (2019–2024) across 13 tertiary centers, contextualized against a historical cohort treated before TAG availability ( n = 40). Patients were elderly (median age 71.5 years) with advanced disease, including skin (93.8%), bone marrow (84.4%), and peripheral blood involvement (53.1%). The overall response rate to TAG was 82.1%, with complete responses in 60.7%. Capillary leak syndrome occurred in 53.1% (grade ≥ 3 in 47.1%), with no unexpected safety signals. With a median follow-up of 18.4 months, 2-year overall survival (OS) and progression-free survival were 40.5% and 30.4%. Nearly half of patients proceeded to allogeneic stem cell transplantation post-TAG, associated with improved survival consistent with the primary analysis and landmark-adjusted analyses (HR 0.25 [0.06–1.14]; p = 0.073). Propensity score–matched comparison with the Non-TAG cohort showed comparable 2-year OS (59.4% vs 60.8%; p = 0.9). Frontline TAG was not associated with OS in pooled multivariable regression (HR 0.89 [0.37–2.15]; p = 0.803), while peripheral blood involvement remained associated with reduced OS (HR 2.63, 95% CI 1.1–6.27; p = 0.03). In this large multicenter real-world cohort, frontline TAG achieved high response rates with manageable toxicity. While unmeasured selection may contribute to the higher transplantation rate after TAG, durable remissions were achieved in patients undergoing post-TAG consolidation, supporting TAG as an induction and bridging strategy to allogeneic stem cell transplantation.

Authors

Institutions

Publication Details

Journal
Journal of Hematology & Oncology
Published
2026-10-07
DOI
https://doi.org/10.1186/s13045-026-01848-w
Primary Topic
Histiocytic Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario

Niklas Gebauer, David Baden, Snjezana Janjetovic, Giuliano Filippini Velázquez et al.
Journal of Hematology & Oncology
Histiocytic Disorders and Treatments
article

Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario

Niklas Gebauer, David Baden, Snjezana Janjetovic, Giuliano Filippini Velázquez, Philipp Berning, Jan C. Schroeder, Ulrike Bacher, Christoph Schliemann, Philipp Faustmann, Hristo Boyadzhiev, Maher Hanoun, Thomas Melchardt, Claudia Lengerke, Evgenii Shumilov, Tim Sauer, Anna Ossami Saidy, Veit Bücklein, Rebecca Wurm-Kuczera, Ulrich Keller, Susanne von Kroge, Jan-Henrik Mikesch, Hanna K. Zieger, Paul J. Bröckelmann, Thomas Pabst, Georg Lenz, Friederike Hildebrand
article en

Abstract

Abstract Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN). Multicenter real-world outcomes and the contribution of up-front consolidation post-TAG remain less defined. We retrospectively analyzed 32 patients with BPDCN treated with frontline TAG (2019–2024) across 13 tertiary centers, contextualized against a historical cohort treated before TAG availability ( n = 40). Patients were elderly (median age 71.5 years) with advanced disease, including skin (93.8%), bone marrow (84.4%), and peripheral blood involvement (53.1%). The overall response rate to TAG was 82.1%, with complete responses in 60.7%. Capillary leak syndrome occurred in 53.1% (grade ≥ 3 in 47.1%), with no unexpected safety signals. With a median follow-up of 18.4 months, 2-year overall survival (OS) and progression-free survival were 40.5% and 30.4%. Nearly half of patients proceeded to allogeneic stem cell transplantation post-TAG, associated with improved survival consistent with the primary analysis and landmark-adjusted analyses (HR 0.25 [0.06–1.14]; p = 0.073). Propensity score–matched comparison with the Non-TAG cohort showed comparable 2-year OS (59.4% vs 60.8%; p = 0.9). Frontline TAG was not associated with OS in pooled multivariable regression (HR 0.89 [0.37–2.15]; p = 0.803), while peripheral blood involvement remained associated with reduced OS (HR 2.63, 95% CI 1.1–6.27; p = 0.03). In this large multicenter real-world cohort, frontline TAG achieved high response rates with manageable toxicity. While unmeasured selection may contribute to the higher transplantation rate after TAG, durable remissions were achieved in patients undergoing post-TAG consolidation, supporting TAG as an induction and bridging strategy to allogeneic stem cell transplantation.

Journal of Hematology & OncologyVol. 19(1)
University of Bern (CH), Universität Hamburg (DE), University of Augsburg (DE), University of Cologne (DE), Heidelberg University (DE), University of Münster (DE), Paracelsus Medical University (AT), University Hospital of Bern (CH), University Hospital Augsburg (DE), University Hospital Heidelberg (DE), LMU Klinikum (DE), Universitätsklinikum Tübingen (DE), University Hospital Münster (DE), University Medical Center Hamburg-Eppendorf (DE), University Hospital Schleswig-Holstein (DE), Essen University Hospital (DE), University Children's Hospital Tübingen (DE), University Cancer Center Hamburg (DE), Klinikum Bremen-Mitte (DE), University Hospital Cologne (DE), Helios Hospital Berlin-Buch (DE), Franklin University (US), University of Duisburg-Essen (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE), University of Lübeck (DE)
Openalex Percentile: Top 13%
Histiocytic Disorders and Treatments
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.